Brain Images–What Do They Mean?
Benedict Carey of The New York Times reports with a degree of healthy skepticism about the latest scientific hoopla: Neuroscientists’ infatuation with brain imaging techniques.
Scientific integrity: ?Truth? versus method
"This is a critical moment: if the system of peer-review is not any longer able to guarantee the reliability of scientific research, this means that science has lost its way."
Coalition letter to Charles Curie, Administrator, SAMHSA
We are, however, very distressed at what appears to us to be a significant discrepancy between your statements and the reality of SAMHSA’s role in implementing the NFC report recommendations, as well as other discrepancies between your statements and SAMHSA’s actions.
Institute of Medicine Committee: FDA drug label “is irrelevant”
"It’s not a question of just knowing the risks and it’s not a question of labeling against risk. The question is how do you change behavior?"
FDA is Selling the Brooklyn Bridge
This issue is NOT about trial lawyers, this issue is about the rights and health, and safety of ordinary citizens.
“this was a drug bill written by and for lobbyists”
Two items in today’s New York Times illustrate the contrast between what the Administration claims it’s legislative / regulatory proposals will do for health care, and what they actually do after they’ve taken effect.
NIMH-funded antidepression drug efficacy / safety studies_What do they prove?
Two studies purporting to report “new encouraging” findings about the efficacy and safety of antidepressants—as tested in the “real world”—were published on Sunday by The American Journal of Psychiatry with an accompanying editorial by Dr. Thomas Insel, director of these studies’ funding agency, the National Institute of Mental Health.
Depression-Serotonin: How Did So Many Smart People Get it So Wrong?_WSJ
"Serotonin and depression: A disconnect between the advertisements and the scientific literature."
"Some 19 million people in the U.S. suffer from depression in any given year. For many, SSRIs help little, if at all. To do better, we have to get the science right." Sharon Begley, Wall Street Journal
How the Drug Industry Is Branding Itself With Bioethics
Dr. Carl Elliott's insightful essay in SLATE:: Why do drug companies want to give money to bioethicists in the first place? In the public relations business, this approach is called "third-party strategy."
Concealed Data | Conflict of Interest | Current Controversies | Hazards | Psych Drugs | Vulnerable Groups
MAD IN AMERICA – important new book
January 7, 2002 FYI MAD IN AMERICA (Perseus Press), a new book by Robert Whitaker, a prize winning science journalist, is sure to cause a stir. Whitaker holds psychiatry’s feet to the fire by examining the evidence in the professional psychiatric literature, FDA documents, published treatment outcome studies–including the World…